KR20230051583A - Crf2 수용체 작용제 및 치료에서의 이의 용도 - Google Patents

Crf2 수용체 작용제 및 치료에서의 이의 용도 Download PDF

Info

Publication number
KR20230051583A
KR20230051583A KR1020237009381A KR20237009381A KR20230051583A KR 20230051583 A KR20230051583 A KR 20230051583A KR 1020237009381 A KR1020237009381 A KR 1020237009381A KR 20237009381 A KR20237009381 A KR 20237009381A KR 20230051583 A KR20230051583 A KR 20230051583A
Authority
KR
South Korea
Prior art keywords
lys
gln
leu
lysine
glutamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237009381A
Other languages
English (en)
Korean (ko)
Inventor
스테판 일리아노
로렌스 루카츠
라이티티아 레데인
필립 보베르제
필리프 자니악
마리-로라 오주윅스
니스 홀란드
지유 리
랄프 엘버트
안드레 에버스
엘리자베타 비앙키
앨리샤 산토프레테
다니엘라 로베르시
마르티나 트리페피
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 filed Critical 사노피
Publication of KR20230051583A publication Critical patent/KR20230051583A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237009381A 2020-08-19 2021-08-18 Crf2 수용체 작용제 및 치료에서의 이의 용도 Pending KR20230051583A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20315387.9 2020-08-19
EP20315387 2020-08-19
PCT/EP2021/072923 WO2022038179A1 (en) 2020-08-19 2021-08-18 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
KR20230051583A true KR20230051583A (ko) 2023-04-18

Family

ID=72615799

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237009381A Pending KR20230051583A (ko) 2020-08-19 2021-08-18 Crf2 수용체 작용제 및 치료에서의 이의 용도

Country Status (16)

Country Link
US (1) US20250243255A1 (enExample)
EP (2) EP4199946B1 (enExample)
JP (1) JP7832927B2 (enExample)
KR (1) KR20230051583A (enExample)
CN (1) CN116472053A (enExample)
AU (1) AU2021328673A1 (enExample)
CA (1) CA3192032A1 (enExample)
ES (1) ES2988026T3 (enExample)
HR (1) HRP20240906T1 (enExample)
HU (1) HUE066991T2 (enExample)
IL (1) IL300464A (enExample)
IS (1) IS3063B (enExample)
MX (1) MX2023002087A (enExample)
PL (1) PL4199946T3 (enExample)
WO (1) WO2022038179A1 (enExample)
ZA (1) ZA202301784B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025230248A1 (ko) * 2024-04-30 2025-11-06 한미약품 주식회사 Crf2 수용체 작용제와 그 아실화 결합체의 용도

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
EP4234574A1 (en) * 2022-02-23 2023-08-30 Corteria Pharmaceuticals Crf2 receptor agonists and their use in therapy
WO2025104264A1 (en) 2023-11-17 2025-05-22 Gubra A/S Hcrhr2 selective polypeptides
TW202544027A (zh) * 2024-04-19 2025-11-16 美商紐羅克里生物科學有限公司 促皮質素釋放因子受體２（ｃｒｆｒ２）促效劑
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CN104356224A (zh) 2014-10-24 2015-02-18 杭州阿德莱诺泰制药技术有限公司 一种制备萨摩鲁泰的方法
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025230248A1 (ko) * 2024-04-30 2025-11-06 한미약품 주식회사 Crf2 수용체 작용제와 그 아실화 결합체의 용도

Also Published As

Publication number Publication date
HRP20240906T1 (hr) 2024-10-11
EP4199946A1 (en) 2023-06-28
ZA202301784B (en) 2024-01-31
EP4435001A3 (en) 2024-10-09
WO2022038179A1 (en) 2022-02-24
PL4199946T3 (pl) 2024-08-19
IL300464A (en) 2023-04-01
HUE066991T2 (hu) 2024-09-28
MX2023002087A (es) 2023-03-23
AU2021328673A1 (en) 2023-03-30
JP2023541798A (ja) 2023-10-04
CN116472053A (zh) 2023-07-21
JP7832927B2 (ja) 2026-03-18
EP4199946C0 (en) 2024-06-05
IS3063B (is) 2025-06-15
US20250243255A1 (en) 2025-07-31
EP4435001A2 (en) 2024-09-25
ES2988026T3 (es) 2024-11-19
CA3192032A1 (en) 2022-02-24
EP4199946B1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
ES2988026T3 (es) Agonistas del receptor CRF2 y su uso en terapia
CN111491658B (zh) 肠促胰岛素类似物及其用途
KR102440323B1 (ko) 인크레틴 유사체 및 그의 용도
JP7295871B2 (ja) 修飾された脂質化リラキシンｂ鎖ペプチドおよびその治療的使用
KR102886870B1 (ko) 이중 수용체 아고니즘 작용을 갖는 폴리펩티드 유도체 및 그 용도
CN114787183A (zh) 肠促胰岛素类似物及其用途
EP4482578B1 (en) Crf2 receptor agonists and their use in therapy
TW201940504A (zh) 經修飾之脂質化鬆弛素ｂ鏈胜肽及其治療用途
AU2024215381A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
RU2845766C1 (ru) Агонисты рецептора crf2 и их применение в терапии
JP2026071260A (ja) Ｃｒｆ２受容体アゴニスト及び治療におけるその使用
HK40087027B (en) Crf2 receptor agonists and their use in therapy
HK40087027A (en) Crf2 receptor agonists and their use in therapy
HK40095414A (en) Crf2 receptor agonists and their use in therapy
WO2024213022A1 (zh) 肠促胰素类似物及其制备方法和应用
HK40112064A (zh) Crf2受体激动剂及其在治疗中的用途

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902